Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Rises By 467.7%

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant growth in short interest in the month of June. As of June 15th, there was short interest totalling 266,800 shares, a growth of 467.7% from the May 31st total of 47,000 shares. Currently, 15.4% of the company’s shares are short sold. Based on an average daily trading volume, of 1,390,000 shares, the days-to-cover ratio is currently 0.2 days.

Virax Biolabs Group Price Performance

Shares of Virax Biolabs Group stock traded down $0.04 during trading on Friday, hitting $1.14. 15,279 shares of the company were exchanged, compared to its average volume of 776,597. The firm’s fifty day moving average price is $1.07 and its 200 day moving average price is $1.03. Virax Biolabs Group has a 1-year low of $0.60 and a 1-year high of $4.30.

Institutional Investors Weigh In On Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. Armistice Capital LLC acquired a new stake in Virax Biolabs Group Limited (NASDAQ:VRAX) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned 7.87% of Virax Biolabs Group as of its most recent filing with the SEC. Institutional investors own 8.61% of the company’s stock.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.